A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Claudia P. Arevalo(University of Pennsylvania), Scott E. Hensley(University of Pennsylvania), Seema S. Lakdawala(Emory University), Valerie Le Sage(University of Pittsburgh), Marcus J. Bolton(University of Pennsylvania), Colleen Furey(University of Pennsylvania), Elizabeth M. Drapeau(University of Pennsylvania), Steven H.Y. Fan(Acuitas Therapeutics (Canada)), Kaela Parkhouse(University of Pennsylvania), Tyler A. Garretson(University of Pennsylvania), Ying K. Tam(Arbutus Biopharma (Canada)), Norbert Pardi(University of Pennsylvania), Drew Weissman(California University of Pennsylvania), Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Louise H. Moncla(University of Pennsylvania), Jeffrey S. Morris(The University of Texas MD Anderson Cancer Center), Hiromi Muramatsu(University of Pennsylvania), Naiqing Ye(University of Pennsylvania)
Cited by 345
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k